Looking ahead, the extension of FLT3-targeted strategies to other hematologic malignancies such as MDS and even to solid tumors with aberrant FLT3 expression, represents an exciting frontier for future investigation. This evidence concerns the gene FLT3 and myelodysplastic syndrome.